<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="185076">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684619</url>
  </required_header>
  <id_info>
    <org_study_id>LN_GMALLE_2004_55</org_study_id>
    <nct_id>NCT00684619</nct_id>
  </id_info>
  <brief_title>506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)</brief_title>
  <official_title>Phase II-Study With Nelarabine in Patients With Refractory Oder Relapsed T- ALL or T-lymphoblastic Lymphoma (Amend.7)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Nelarabine is effective in the treatment
      of patients with T-ALL/NHL in order to achieve a complete remission followed by an early
      stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability and Efficacy of Compound GW506U78 in relapsed/refractory T-ALL/NHL</measure>
    <time_frame>after 1 cycle and 2 cycles</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>T-ALL, T-NHL (Lymphoblastic)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelarabine</intervention_name>
    <description>1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5</description>
    <other_name>Compound 506U78</other_name>
    <other_name>Atriance</other_name>
    <other_name>Arranon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T-ALL; T-NHL

          -  age &gt;= 18 years

          -  cytological treatment failure / relapse

          -  molecular treatment failure / relapse

          -  no promising therapy alternatives with approved medication available

          -  no CNS-manifestation, requiring intrathecal therapy or CNS-radiation

          -  no convulsive disease or neurotoxicity &gt; grade III in patients history

          -  written informed consent

          -  no cytostatic therapy in the last 10 days

          -  no pregnancy or breastfeeding

          -  effective contraception

          -  recovery of toxicities of previous chemotherapy - except leukemia- related changes
             like bone marrow suppression or pathological transaminases in liver manifestation

        Exclusion Criteria:

          -  Severe psychiatric illness

          -  uncontrolled or severe cardiac disease or infection

          -  active secondary neoplasms - except skin cancer (no melanoma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Hoelzer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Frankfurt, Medical Dept. II</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Frankfurt, Medical Dept. II</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Münster</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der FSU Jena</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leukemia-trials.eu</url>
    <description>European Leukemia Trial Registry</description>
  </link>
  <verification_date>May 2008</verification_date>
  <lastchanged_date>August 20, 2010</lastchanged_date>
  <firstreceived_date>May 16, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Dieter Hoelzer, MD, PhD</name_title>
    <organization>University Hospital of Frankfurt</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
